US2005043243A1PendingUtilityA1

Adipocyte-specific protein homologs

66
Priority: Jul 18, 1997Filed: Sep 23, 2004Published: Feb 24, 2005
Est. expiryJul 18, 2017(expired)· nominal 20-yr term from priority
Inventors:Paul O. Sheppard
C07K 2319/00A61K 48/00C12N 2799/022C07K 14/4702A61K 38/00
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to polynucleotide and polypeptide molecules for zsig37, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig37 polypeptides.

Claims

exact text as granted — not AI-modified
1 . A formulation comprising a pharmaceutically acceptable vehicle and a polypeptide, wherein the polypeptide comprises amino acid residues 26 to 281 of SEQ ID NO:2.  
     
     
         2 . The formulation of  claim 1 , wherein the polypeptide comprises amino acid residues 22 to 281 of SEQ ID NO:2.  
     
     
         3 . The formulation of  claim 1 , wherein the polypeptide comprises amino acid residues 1 to 281 of SEQ ID NO:2.  
     
     
         4 . The formulation of  claim 1 , wherein the polypeptide consists of amino acid residues 26 to 281 of SEQ ID NO:2.  
     
     
         5 . The formulation of  claim 1 , wherein the formulation comprises a complex of at least two of the polypeptides.  
     
     
         6 . The formulation of  claim 5 , wherein the polypeptides are linked by intermolecular disulfide bonds.  
     
     
         7 . The formulation of  claim 5 , wherein the polypeptide complex is a trimer.  
     
     
         8 . The formulation of  claim 5 , wherein the polypeptide complex is a hexamer.  
     
     
         9 . The formulation of  claim 5 , wherein the polypeptide complex is an 18mer.  
     
     
         10 . A formulation consisting of a pharmaceutically acceptable vehicle and a polypeptide, wherein the polypeptide comprises amino acid residues 26 to 281 of SEQ ID NO:2.  
     
     
         11 . The formulation of  claim 10 , wherein the polypeptide comprises amino acid residues 22 to 281 of SEQ ID NO:2.  
     
     
         12 . The formulation of  claim 10 , wherein the polypeptide comprises amino acid residues 1 to 281 of SEQ ID NO:2.  
     
     
         13 . The formulation of  claim 10 , wherein the polypeptide consists of amino acid residues 26 to 281 of SEQ ID NO:2.  
     
     
         14 . The formulation of  claim 10 , wherein the formulation comprises a complex of at least two of the polypeptides.  
     
     
         15 . The formulation of  claim 14 , wherein the polypeptides are linked by intermolecular disulfide bonds.  
     
     
         16 . The formulation of  claim 14 , wherein the polypeptide complex is a trimer.  
     
     
         17 . The formulation of  claim 14 , wherein the polypeptide complex is a hexamer.  
     
     
         18 . The formulation of  claim 14 , wherein the polypeptide complex is an 18mer.  
     
     
         19 . A formulation comprising a pharmaceutically acceptable vehicle and a polypeptide, wherein the polypeptide comprises amino acid residues 26 to 281 of SEQ ID NO:2, and wherein the polypeptide is recombinantly produced in a eukarotyic or prokaryotic cell.  
     
     
         20 . The formulation of  claim 19  wherein the polypeptide is recombinantly produced in a mammalian cell.  
     
     
         21 . The formulation of  claim 19  wherein the polypeptide is recombinantly produced in  E. coli.

Join the waitlist — get patent alerts

Track US2005043243A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.